| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0008 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |